首页 / 产品 / 抗体 / 一抗

Mouse Monoclonal CD85K Antibody

  • 中文名: CD85K抗体
  • 别    名: ILT3; LIR5; LILRB4; ILT-3; LIR-5
货号: IPD32039
Price: ¥1280
数量:
大包装询价

验证与应用

应用及物种
WB 咨询技术 Human,Mouse,Rat
IF 咨询技术 Human,Mouse,Rat
IHC 1/200 - 1/1000 Human,Mouse,Rat
ICC 1/200 - 1/1000 Human,Mouse,Rat
FCM 1/200 - 1/400 Human,Mouse,Rat
Elisa 1/10000 Human,Mouse,Rat

产品详情

参考文献

以下是关于CD85K(假设为免疫调节受体相关分子)抗体的假设性参考文献示例,基于常见的相关研究方向整理:

---

1. **文献名称**: "CD85K as a Novel Immune Checkpoint in Tumor Microenvironment"

**作者**: Smith A, et al.

**摘要**: 研究报道了CD85K在肿瘤相关巨噬细胞(TAMs)中的高表达,并开发了一种拮抗性抗体。实验显示,阻断CD85K可增强T细胞抗肿瘤活性,抑制小鼠模型中黑色素瘤的生长,提示其作为免疫治疗靶点的潜力。

2. **文献名称**: "Characterization of CD85K Antibody for Modulating Dendritic Cell Function"

**作者**: Zhang L, et al.

**摘要**: 通过单克隆抗体技术筛选出CD85K抗体,发现其可抑制树突状细胞(DCs)的促炎因子分泌,降低Th17细胞分化,可能用于自身免疫疾病(如类风湿性关节炎)的治疗。

3. **文献名称**: "CD85K Interaction with Viral Proteins and Therapeutic Antibody Development"

**作者**: Tanaka K, et al.

**摘要**: 研究揭示了CD85K与EB病毒蛋白的相互作用机制,并开发了阻断该通路的中和抗体。体外实验表明,该抗体可减少B细胞感染,为抗病毒治疗提供新策略。

4. **文献名称**: "Structural Insights into CD85K Antigen-Antibody Complexes"

**作者**: Müller R, et al.

**摘要**: 通过X射线晶体学解析了CD85K与其单克隆抗体的结合表位,发现抗体通过干扰配体结合域抑制下游信号传导,为优化治疗性抗体设计提供结构基础。

---

**注意**:CD85K的命名可能存在差异(如属于LILR或KIR家族),建议通过数据库(如PubMed)以“CD85K”、“LILRB”或“免疫检查点抗体”为关键词检索最新文献。若研究目标明确,需核实分子标准命名及研究背景。

背景信息

CD85K, also known as KIR3DL2 (Killer Cell Immunoglobulin-like Receptor 3DL2), is a transmembrane protein belonging to the immunoglobulin superfamily. It is primarily expressed on natural killer (NK) cells and subsets of T lymphocytes, where it functions as a regulatory receptor modulating immune responses. Structurally, CD85K contains three extracellular immunoglobulin-like domains, a transmembrane region, and a cytoplasmic tail with immunoreceptor tyrosine-based inhibitory motifs (ITIMs). These motifs enable it to transmit inhibitory signals upon ligand binding, counteracting activating signals to maintain immune homeostasis.

CD85K interacts with HLA class I molecules, particularly HLA-A3 and HLA-A11 allotypes, though its ligand specificity may vary. This interaction plays a role in distinguishing healthy cells from infected or malignant cells by monitoring MHC class I expression, a mechanism critical for NK cell tolerance. Dysregulation of CD85K has been implicated in autoimmune disorders, viral evasion, and cancer progression. For example, in cutaneous T-cell lymphomas (CTCL), CD85K is overexpressed on malignant T cells, serving as a diagnostic marker and therapeutic target. Recent studies explore CD85K-targeted monoclonal antibodies and CAR-T cell therapies to exploit its disease-specific expression. Despite functional similarities with other KIR family members, CD85K's unique ligand interactions and tissue-specific roles continue to drive research in immunotherapy and immune regulation.

客户数据及评论

折叠内容

大包装询价

×